title: Syk and tired of current chronic GVHD therapies.
abstract: In this issue of Blood, Flynn et al1 provide key data that lend further support to the development of clinical trials of spleen tyrosine kinase (Syk) inhibition for more effective chronic graft-versus-host disease (cGVHD) treatment.
authors.affiliation: NATIONAL CANCER INSTITUTE.
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Fowler
authors.affiliation: NATIONAL CANCER INSTITUTE.
authors.forename: Steven Z
authors.initials: SZ
authors.lastname: Pavletic
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000201:enzymology*; D005260:Female; D006086:Graft vs Host Disease / Q000201:enzymology*; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism*; D008213:Lymphocyte Activation / Q000276:immunology*; D011505:Protein-Tyrosine Kinases / Q000378:metabolism*
chemical_list: D047908:Intracellular Signaling Peptides and Proteins; D011505:Protein-Tyrosine Kinases